Category: BioTech

Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

International Game Technology Reports Solid 2Q Results; Shares Moderately Undervalued

International Game Technology IGT reported solid secondquarter results in line with our expectations. Revenue increased 11% to $600 million (compared with consensus of $572 million) and EBITDA increased 6% to $247 million (consensus of $200 million). The increase in revenue was driven by a 16% rise in product sales, primarily due to strong sales of video lottery terminals in Canada, sales to new casinos in … Continue reading International Game Technology Reports Solid 2Q Results; Shares Moderately Undervalued

John MeadyLeave a comment
BioTech, Finance

Biotech Stock News: Jazz Pharma Shares Go Up Due to Defibrotide Buy

Jazz Pharmaceuticals (JAZZ) shares climbed 6.97% after the company announced that it has entered into an agreement to acquire the rights to defibrotide from Sigma-Tau Pharmaceuticals, Inc. The deal is expected to close in the third quarter of 2014. Sigma-Tau held the rights to defibrotide on the basis of an agreement with Gentium, which was acquired by Jazz Pharma earlier this year. Jazz Pharma markets … Continue reading Biotech Stock News: Jazz Pharma Shares Go Up Due to Defibrotide Buy

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Ingram Micro Sees More IT Spending Across All Regions

We are maintaining our fair value estimate and economic moat rating for Ingram Micro IM after the company reported solid first-quarter results that indicated consumers across the globe are spending more on IT. Ingram Micro’s sales grew 19% year-over-year to $10.6 billion, with the 2012 BrightPoints and Aptec acquisitions adding $1.85 billion, or 13%, to the top-line. Organic sales added 6% growth. Encouragingly, the company … Continue reading Ingram Micro Sees More IT Spending Across All Regions

John MeadyLeave a comment
BioTech, Finance

Biotech Stocks Under Focus: Vertex Pharma Captures Headlines

Vertex Pharmaceuticals’ (VRTX) cystic fibrosis (CF) drug, Kalydeco (ivacaftor) won a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for use in CF patients (6 years of age and above) with one of eight non-G551D gating mutations in the cystic fibrosis trans membrane conductance regulator (CFTR) gene. Kalydeco is already approved in the EU for CF patients (6 years of … Continue reading Biotech Stocks Under Focus: Vertex Pharma Captures Headlines

Richard Atkins
FB Nasdaq FB Facebook
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Discover’s Momentum Continues in 1Q

Discover Financial Service DFS reported net income of $673 million, or $1.33 per diluted share, for the first quarter of 2013. The narrow-moat company continued to generate strong momentum across business lines, increasing book value more than 5% during the quarter, and we may moderately increase our fair value estimate as we incorporate the quarter’s results and transfer coverage to a new analyst. In contrast … Continue reading Discover’s Momentum Continues in 1Q

John MeadyLeave a comment
BioTech, Finance

Biotech Stock in Focus: Bayer Continues Progress with Eylea

Bayer’s (BAYRY) has progressed well with its newly launched products in the last few quarters. Drugs like Eylea (Eye), Stivarga (oncology), Xarelto (anticoagulant), Xofigo (oncology) and Adempas (pulmonary hypertension) posted sales of €598 million in the first quarter and are expected to contribute around €2.8 billion in 2014. The company is looking to get these products approved for additional indications as well. Last week, Bayer … Continue reading Biotech Stock in Focus: Bayer Continues Progress with Eylea

Richard Atkins